DanDrit Biotech USA
2001
FOUNDED
PUBLIC
STATUS
1-10
EMPLOYEES
ENOB
STOCK SYMBOL
$3.78
SHARE PRICE
(As of Thursday Closing)
Description
Developer of the world's first vaccine against colorectal cancer. The company's business focuses on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer.
Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 375 Park Avenue
- Suite 2607
- New York, NY 10152
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore DanDrit Biotech USA’s full profile, request a free trial.
DanDrit Biotech USA Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $1.60 - $6.85 | $148M | $4.10 | 7.64K | 36.2M |
DanDrit Biotech USA Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2018
|
FY 2017
30-Jun-2017
|
FY 2016
30-Jun-2016
|
FY 2015
30-Jun-2015
|
|---|---|---|---|---|
| Enterprise Value | 76,510 | 21,771 | 23,913 | 59,263 |
| Revenue | 0 | 0 | 43 | |
| EBITDA | (3,678) | (2,167) | (2,168) | (3,028) |
| Net Income | (4,448) | (2,143) | (1,735) | (2,673) |
| Total Assets | 4,522 | 871 | 2,073 | |
| Total Debt | 0 | 2,090 | 103 | 101 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
DanDrit Biotech USA Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore DanDrit Biotech USA‘s full profile, request access.
Request full access to PitchBook